The retina is a transparent light-sensitive structure at the back of the eye. The central part of the retina is the macula, which contains a high density of light-sensitive cells that produce the clearest visual images and are primarily responsible for central vision and color vision.
Age-related macular degeneration (AMD) is a progressive fundus disorder in which the macula undergoes progressive lesions that severely impair vision and visual function. AMD causes progressive loss of central vision, difficulty seeing details of objects, and curved straight lines, and is an important cause of irreversible blindness in the elderly population. AMD is caused by a combination of factors, of which smoking, age, and genetic predisposition are key factors.
Clinically, there are two types of AMD, dry (non-exudative or atrophic) and wet (neovascular or exudative), and although all AMD begins as dry, about 10% will go on to develop wet AMD. although only a modest percentage of patients are wet, 80%-90% of severe vision loss due to AMD comes from wet.
Figure 1. Fundus photographs in health and AMD. (Jayakrishna A., et al., 2012)
(A, the ocular fundus of a healthy eye; B, the late-stage dry form of AMD; C, wet AMD.)
The prevalence of AMD is increasing each year in all countries, and the number of people with AMD is expected to increase to 288 million worldwide by 2040. Dietary changes may help slow the progression of the lesion, and some patients may require intraocular injections or laser treatment.
Human pigment epithelium-derived factor (PEDF), one of the most potent known anti-angiogenic proteins found in humans, is a key natural regulator of normal blood vessel growth and neuronal function in the eye, typically regulating blood vessel growth and protecting retinal cells from damage in the eye, and has been shown to have dual potent anti-angiogenic and neuroprotective functions.
AdPEDF is an adenovirus-based vector containing the gene for PEDF, designed to provide sustained levels of PEDF protein to the eye. Creative BioMart offers AdPEDF to researchers in the retina, eye nerve, and other ophthalmology-related fields, as AdPEDF is being developed for the treatment of AMD, where it has been shown to rapidly increase intraocular AdPEDF protein levels, inhibit abnormal blood vessel growth and cause abnormal blood vessels to subside while protecting the eye's photoreceptors.
Creative BioMart has been following the progress in the attack of ophthalmic diseases, and we offer products that are designed to help researchers research the treatment of age-related macular degeneration disease. If you need to purchase the product or have questions about the product we provide, you can contact our staff by submitting information online or sending an email, and we will contact you as soon as we receive your information to provide you with the most appropriate solution.
- Wei L., et al., (2005). "Adenovector pigment epithelium-derived factor (AdPEDF) delivery for wet age-related macular degeneration." Retina, 25(8 Suppl): S48-S49.
- Jayakrishna A., et al., (2012). "Mechanisms of Age-Related Macular Degeneration." Neuron, 75(1): 26-39.